On December 22nd, the Hong Kong Stock Exchange witnessed another grand occasion with the simultaneous ringing of four gongs. Exclusive industry advisor Frost & Sullivan extended their warmest congratulations.Nanhua Futures (2691.HK),Ming Kee Hospital (2581.HK),Hua Fen Biology (2396.HK),Impression Dahongpao (2695.HK)Successfully listed on the Hong Kong Stock Exchange!
All four companies have chosen Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) as their trusted partner, providing them with exclusive industry advisory services! We cherish and are grateful for the choices and trust of our customers, and we will live up to our commitments by continuing to accompany more companies on their capital market journey towards higher-quality development with professional services!
Frost & Sullivan has always been a leader in helping companies go public in Hong Kong. According to LiveReport's big data (statistical data as of September 30, 2025), from January to September 2025, and during the past 12 and 36 months, Frost & Sullivan provided listing industry advisory services for 47 (market share 72%), 62 (market share 69%), and 162 (market share 70%) Hong Kong IPOs respectively, ranking first in terms of number. It has a wealth of industry experience and communication skills with regulatory authorities, exchanges, investment and financing institutions, and various related organizations.
Nanhua Futures Co., Ltd. (Stock Code: 2691.HK)
Nanhua Futures Co., Ltd.Positioned as a leading futures company in China, it provides futures and derivatives services both domestically and internationally by virtue of its in-depth understanding of the needs of Chinese and overseas clients, as well as its keen insight into the global financial and derivatives markets.
BenQ Healthcare Group Co., Ltd. (Stock Code: 2581.HK)
BenQ Healthcare Group Co., Ltd.It is a private for-profit comprehensive hospital group in the Chinese mainland, currently owning and operating two private for-profit comprehensive hospitals. Calculated based on total revenue in 2024, the company is the largest private for-profit comprehensive hospital group in East China, holding a market share of 1.0% in the region; by the same measure, it ranks seventh among all private for-profit comprehensive hospital groups nationwide, with a market share of 0.4% in China; calculated based on average bed income in 2024, the company ranks first among all private for-profit comprehensive hospital groups in mainland China.
Huafeng Biotechnology (Qingdao) Co., Ltd. (Stock Code: 2396.HK)
Huafeng Biotechnology (Qingdao) Co., Ltd.It is an innovative biopharmaceutical company with wound healing and tissue repair as its core research direction. The company selects indications that meet unmet clinical needs, deeply invests in the field of wound healing treatment, and takes platelet-derived growth factor (PDGF)-related drugs as its core R&D pipeline.
Impression Dahongpao Co., Ltd. (Stock Code: 2695.HK)
Impression Dahongpao Co., Ltd.It is a leading cultural and tourism performance company in China, dedicated to building immersive cultural and tourism experiences around local characteristic cultural resources. Its business mainly includes performance services, Impression Cultural and Tourism Town business, and tea soup hotel business.
During the process of an enterprise going public in Hong Kong, Frost & Sullivan mainly undertakes the following tasks: helping issuers accurately and objectively understand their positioning in the target market, using objective market data to discover, support, and highlight the issuer's competitive advantages, assisting the issuer, investment banks, and other intermediaries in completing the relevant parts of the prospectus (such as the overview, competitive advantages and strategy, industry overview, business, and other important sections), helping the issuer complete communication with the Hong Kong Stock Exchange and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on various industry-related issues from the Hong Kong Stock Exchange, etc.
Since the Frost & Sullivan team began providing investment and financing advisory services to corporate leaders and their management teams, it has helped nearly three thousand companies successfully list in Hong Kong and overseas, making it a leading enterprise in the field of domestic investment and financing strategy consulting. Frost & Sullivan has long cooperated closely with globally renowned investment banks, audit firms, law firms, investment institutions, and industry-leading companies, establishing an efficient domestic investment and financing demand matching platform that can quickly form comprehensive consulting service teams. Over the past decade, Frost & Sullivan has continuously ranked first in the market share of professional industry advisory services for Chinese companies listing in Hong Kong and overseas; moreover, in recent years, Frost & Sullivan reports have been widely cited in the prospectuses of leading A-share and STAR Market listed companies, as well as in primary and secondary market research reports and other capital market disclosure documents.
